ROR
RAR-related orphan receptor
Retinoic acid receptor-related orphan receptors (RORs) are a subfamily of the thyroid hormone receptor, which is a subfamily of the nuclear receptors and belonging to the orphan nuclear receptor family. The ROR subfamily contains three members: RORα (NR1F1), RORβ (NR1F2), and RORγ (NR1F3) and function as ligand-dependent transcription factors.
RORs are reported to activate transcription through ligand-dependent interactions with co-regulators and are involved in the development of secondary lymphoid tissues, autoimmune diseases, inflammatory diseases, the circadian rhythm, and metabolism homeostasis.
RORα and RORγ are important regulators of the immune system. The development and differentiation of Th17 cells are dependent on these factors. RORγ is expressed in lymphoid tissue inducer cells, innate lymphoid cells, invariant natural killer T cells, and γδ T cells, which contribute to inflammation and autoimmune disease.
ROR Isoform Specific Products
All Product Categories
-
ROR Inhibitors
(59)
View all products
-
ROR Agonists
(29)
View all products
-
ROR Antagonists
(37)
View all products
-
ROR Activators
(2)
View all products
-
ROR Modulators
(8)
View all products
-
ROR Inducer
(1)
View all products
-
ROR Degraders
(2)
View all products
-
ROR Control
(1)
View all products
-
ROR Ligands
(3)
View all products
-
ROR Related Products (148)
Related Products (148)
-
Antibodies (5)
-
ROR Isoform Comparison
-
CS5001 Antibody
0 ImagesCat. No.: HY-P992337
-
PROTAC ROR1 degrader-1
0 ImagesCat. No.: HY-170995PROTAC ROR1 degrader-1 is a ROR1 PROTAC degrader with DC50 values of 40.88 nM (NCI-H23), 69.0 nM (NCI-H460), 83.35 nM (NCI-H1299) and 42.07 nM (NCI-H1975), respectively. PROTAC ROR1 degrader-1 inhibits the proliferation of lung cancer cells and induces apoptosis. PROTAC ROR1 degrader-1 can be used in research related to non-small cell lung cancer.
-
RORB Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS12129RORB Human Pre-designed siRNA Set A contains three designed siRNAs for RORB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
XY039
0 ImagesCat. No.: HY-163611CAS No.: 2118967-75-0
-
RORγt inverse agonist 31
0 ImagesCat. No.: HY-155548CAS No.: 3048344-59-5RORγt inverse agonist 31 (14g) is a potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist, with an IC50 of 0.428 μM. RORγt inverse agonist 31 can alleviate the severity of Imiquimod (HY-B0180)-induced psoriasis in mice.
-
AZ-5104 (GMP)
0 ImagesCat. No.: HY-B0793GCAS No.: 1421373-98-9AZ-5104 GMP is a GMP-grade form of AZ-5104 (HY-B0793). AZ-5104 is an orally active RORγ receptor-active compound, and also a circulating metabolite of AZD9291. AZ-5104 inhibits sensitizing EGFR mutants, EGFRT790M drug-resistant EGFR mutants and wild-type EGFR, while showing no activity against the IGF-1R family. AZ-5104 can be used in the research of non-small cell lung cancer.
-
BL20-MMAE
0 ImagesCat. No.: HY-177109CAS No.: 2765612-38-0BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE (HY-15162) via a BL20 linker.
-
Allolithocholic Acid-d4
0 ImagesCat. No.: HY-143712S1Synonyms: 3α-hydoxy-5α-Cholaoic Acid-d4, allo-LCA-d4Allolithocholic Acid-d4 (3α-hydoxy-5α-Cholaoic Acid-d4, allo-LCA-d4) is deuterium labeled Allolithocholic acid (HY-143712). Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC50 = 2.7 μM) and RORγt inverse agonist (IC50 = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.
-
RORγ agonist 2
0 ImagesCat. No.: HY-175361RORγ agonist 2 (Compound 34) is a selective RORγ agonist with an EC50 of 0.03 μM for hRORγ. RORγ agonist 2 significantly inhibits tumors growth in syngeneic MC38 tumor mice model.
-
huXBR1-402
0 ImagesCat. No.: HY-P992376Synonyms: NBE-002 AntibodyhuXBR1-402 (NBE-002 Antibody) is a high-affinity (Kd=5.8 nM) humanized chimeric rabbit/human monoclonal antibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis).
-
RORγt inverse agonist 34
0 ImagesCat. No.: HY-170370CAS No.: 2247604-77-7RORγt inverse agonist 34 (compound 5a) is a RORγt inverse agonist with an IC50 of 0.094 μM for RORγt-LBD. RORγt inverse agonist 34 is used for psoriasis research.
-
RORγt agonist 4
0 ImagesCat. No.: HY-160021CAS No.: 2241769-59-3RORγt agonist 4 (compound 14) is a potent and selective agonist of RORγt. RORγt agonist 4 significantly enhances metabolic stability. RORγt agonist 4 improves the situation of tumor models of mouse B16F10 melanoma and LLC lung adenocarcinoma.
-
RORγt inverse agonist 37
0 ImagesCat. No.: HY-183763CAS No.: 3134806-34-8RORγt inverse agonist 37 is an orally active RORγt inverse agonist with an IC50 of 10.8 nM against human targets. RORγt inverse agonist 37 destabilizes helix 12 of RORγt in the agonist-bound conformation, thereby inhibiting transcriptional activity. RORγt inverse agonist 37 inhibits the secretion of IL-17 in cells and in LPS-induced systemic inflammation mouse models. RORγt inverse agonist 37 improves disease-related symptoms in mouse models of psoriasiform dermatitis. RORγt inverse agonist 37 can be used in research related to psoriasiform dermatitis and systemic inflammation.
-
ROR1-IN-3
0 ImagesCat. No.: HY-174382ROR1-IN-3 (Compound 24d) is a potent and highly selective ROR1 kinase inhibitor (IC50 = 17.6 nM). ROR1-IN-3 demonstrates robust antitumor activity and inhibitory effect against ROR1 both in vitro and in vivo. ROR1-IN-3 has robust antiproliferative efficacy in vitro and in vivo. ROR1-IN-3 induces apoptosis in cancer cell lines. ROR1-IN-3 inhibits ROR1 downstream AKT/mTOR and NF-κB signaling pathway. ROR1-IN-3 can be studied in antitumor research.
-
RORγt inverse agonist 32
0 ImagesCat. No.: HY-168179CAS No.: 2301159-96-4RORγt inverse agonist 32 (compound b14) is orally active. RORγt inverse agonist 32 can be used in inflammation research.
-
BMS-336
0 ImagesCat. No.: HY-182716CAS No.: 2204226-97-9
